Abstract
Connective tissue remodeling is achieved by a complex process involving several cell types, a plethora of growth factors, cytokines, chemokines and turnover of extracellular matrix (ECM). The main enzymes that degrade ECM molecules are matrix metalloproteinases (MMPs) and their activities are regulated by endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Recent studies have indicated that endothelins and their receptor expression affects tissue remodeling and repair. Endothelins are rapidly produced by endothelial cells in response to tissue injury and they have potent vasoconstrictive properties. They also promote tissue remodeling through activation of resident connective tissue cells and controlling the production of MMPs and TIMPs by the activated cells. In this review we present the cross-talk between the endothelins and the MMP-TIMP system and their implications in controlling the normal and abnormal tissue remodeling.
Keywords: endothelin, matrix metalloproteinases, tissue inhibitors of metalloproteinases, connective tissue remodelling, extracellular matrix, scarring, fibrosis
Current Vascular Pharmacology
Title: Connective Tissue Remodeling: Cross-Talk between Endothelins and Matrix Metalloproteinases
Volume: 3 Issue: 4
Author(s): David Abraham, Markella Ponticos and Hideaki Nagase
Affiliation:
Keywords: endothelin, matrix metalloproteinases, tissue inhibitors of metalloproteinases, connective tissue remodelling, extracellular matrix, scarring, fibrosis
Abstract: Connective tissue remodeling is achieved by a complex process involving several cell types, a plethora of growth factors, cytokines, chemokines and turnover of extracellular matrix (ECM). The main enzymes that degrade ECM molecules are matrix metalloproteinases (MMPs) and their activities are regulated by endogenous inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Recent studies have indicated that endothelins and their receptor expression affects tissue remodeling and repair. Endothelins are rapidly produced by endothelial cells in response to tissue injury and they have potent vasoconstrictive properties. They also promote tissue remodeling through activation of resident connective tissue cells and controlling the production of MMPs and TIMPs by the activated cells. In this review we present the cross-talk between the endothelins and the MMP-TIMP system and their implications in controlling the normal and abnormal tissue remodeling.
Export Options
About this article
Cite this article as:
Abraham David, Ponticos Markella and Nagase Hideaki, Connective Tissue Remodeling: Cross-Talk between Endothelins and Matrix Metalloproteinases, Current Vascular Pharmacology 2005; 3(4) . https://dx.doi.org/10.2174/157016105774329480
DOI https://dx.doi.org/10.2174/157016105774329480 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Role of Tumor Suppressor Dysregulation in Prostate Cancer Progression
Current Drug Targets Pyridine Based Antitumour Compounds Acting at the Colchicine Site
Current Medicinal Chemistry Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Correlation of Fixed Aqueous Layer Thickness Around PEG-modified Liposomes with In Vivo Efficacy of Antitumor Agent-containing Liposomes
Current Drug Discovery Technologies Tumour Targeting with Systemically Administered Bacteria
Current Gene Therapy A Preliminary Study of the Action of Virtosomes from Non-dividing Cells on Tumour Cell Replication in vitro and in vivo
Anti-Cancer Agents in Medicinal Chemistry Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Imatinib (STI571) Resistance in Chronic Myelogenous Leukemia: Molecular Basis of the Underlying Mechanisms and Potential Strategies for Treatment
Mini-Reviews in Medicinal Chemistry Novel Molecular Targets and Mechanisms Involved in the Invasion and Metastasis of Pancreatic Cancer
Clinical Cancer Drugs Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy LNA Antisense: A Review
Current Physical Chemistry Inhibition of Highly Pathogenic Avian H5N1 Influenza Virus Replication by NanoRNA Oligonucleotides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine
CNS & Neurological Disorders - Drug Targets The Cell Wall-Associated Proteins in the Dimorphic Pathogenic Species of Paracoccidioides
Current Protein & Peptide Science Creating A Standard of Care for Fertility Preservation
Current Women`s Health Reviews Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine Gap Junctions as Targets for Cancer Chemoprevention and Chemotherapy
Current Drug Targets Stable Expression of the Sodium/Iodide Symporter (NIS) for anti-Cancer Gene Therapy of Glioma Cells Using a Third Generation Self-Inactivating Lentiviral Vector System in Combination with 211At
Current Radiopharmaceuticals A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery